Nausea · people with moderate to severe cancer pain
It is very uncertain whether hydromorphone changes specific adverse events – nausea compared with morphine (very low certainty).
1 finding from 1 review
Vomiting · people with moderate to severe cancer pain
It is very uncertain whether hydromorphone changes specific adverse events – vomiting compared with morphine (very low certainty).
1 finding from 1 review
Dizziness · people with moderate to severe cancer pain
It is very uncertain whether hydromorphone changes specific adverse events – dizziness compared with morphine (very low certainty).
1 finding from 1 review
Constipation · people with moderate to severe cancer pain
1 finding from 1 review
Quality of life · people with moderate to severe cancer pain
The review found no eligible studies for this question.
1 finding from 1 review
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · people with moderate to severe cancer pain
1 finding from 1 review
Relief of pain · people with moderate to severe cancer pain
It is very uncertain whether hydromorphone changes participant‐reported pain relief compared with morphine (very low certainty).
1 finding from 1 review
Average pain scores (0-100 VAS) · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis
Hydromorphone showed no clear difference in average pain scores (0-100 VAS) compared with morphine; GRADE not reported.
1 finding from 1 review